EGFR and lung carcinoma: Other studies on EGFR-targeting drugs have demonstrated that mesenchymal-type lung cancer cells exhibit an EMT-dependent acquisition of platelet-derived growth factor, fibroblast growth factor receptor, and transforming growth factor beta receptor signaling pathways 11, and integrin-linked kinase is a novel target for overcoming hepatocellular carcinoma resistance to EGFR inhibition 12.